BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) reported today that the Company plans to file a motion for rehearing and rehearing en banc with the U.S. Court of Appeals for the Federal Circuit following the Court’s recent decision regarding the validity of United States Patent No. 5,061,722, a composition of matter patent for ALTACE® (ramipril). Yesterday’s ALTACE® patent decision applied the recent U.S. Supreme Court decision in the KSR International v. Teleflex U.S. case to invalidate the patent on the basis of obviousness. The Company is of the opinion that this application of the law is not consistent with other recent rulings of the Federal Circuit Court. In addition, the Company believes that yesterday’s decision relies on factual inaccuracies.
